Companies in #Chronic Pain

Camurus is a Swedish specialty pharmaceutical company developing and commercializing innovative medicines based on its proprietary FluidCrystal technology platform for long-acting injectable drug delivery. The company focuses on rare diseases, oncology, and CNS disorders.

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology, and fibrotic disease. The company was incorporated in 2009 as Pipeline Therapeutics and renamed Contineum Therapeutics in November 2023 to reflect its expansion into fibrotic indications, and is based in San Diego, California. Its two clinical programs target de-risked mechanisms with existing human data: PIPE-791, an LPA1 receptor antagonist being developed in idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, a selective M1 muscarinic receptor antagonist licensed to Johnson & Johnson as JNJ-5120 and in development for major depressive disorder and remyelination in multiple sclerosis. Contineum listed on Nasdaq in April 2024 and carries a substantial cash balance relative to its operating burn, which leaves the equity sensitive to clinical readouts on its partnered and wholly owned programs rather than to near-term financing risk.

Nexalin Technology is a Houston-based medical device company designing and developing non-invasive neurostimulation products for mental health conditions. Its cranial electrotherapy stimulation (CES) headset devices — Generation 1 through Generation 3 — are designed to treat anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, and Alzheimer's disease/dementia without drugs or psychotherapy. The company listed on Nasdaq in September 2022; on August 27, 2026 its board approved a 1-for-30 reverse stock split to maintain compliance with the Nasdaq bid-price rule, with split-adjusted trading expected to begin August 31, 2026.

Slate Medicines is a clinical-stage biotechnology company developing anti-PACAP therapeutics for migraine and headache disorders. The company launched in 2026 with a $130M Series A to advance its lead program SLTE-1009 and other PACAP-pathway candidates, joining a competitive class of next-generation migraine developers seeking to challenge the CGRP inhibitor standard of care.